This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses

This study has been completed.
Information provided by:
Peplin Identifier:
First received: September 11, 2006
Last updated: January 26, 2016
Last verified: January 2016
The purpose of this study is to determine whether topical application of PEP005 is safe for the treatment of actinic keratoses.

Condition Intervention Phase
Actinic Keratosis Drug: PEP005 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.

Resource links provided by NLM:

Further study details as provided by Peplin:

Primary Outcome Measures:
  • Safety

Secondary Outcome Measures:
  • Resolution of AK

Estimated Enrollment: 200
Study Start Date: September 2006
Study Completion Date: June 2007
Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)
Detailed Description:
Actinic keratoses (AK) is a common skin condition characterized by rough, scaly patches or sores on the top layer of the skin which if left untreated can progress to skin cancer. Current treatments can cause scarring and hypopigmentation, be inconvenient, or require long treatment duration. Non-invasive alternative therapy for treatment of AK lesions is thus being researched.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  1. Male patients at least 18 years of age.
  2. Post-menopausal female patients i.e., no menses for at least 12 consecutive months, or without a uterus.
  3. 4 to 8 clinically typical, visible and discrete AK lesions within a contiguous 25 cm2 treatment area on the arm, shoulder, chest, back or scalp.
  4. Screening laboratory values within the reference ranges as defined by the central laboratory or "out of range" test results that are clinically acceptable to the Investigator.
  5. Ability to follow study instructions and likely to complete all study requirements.
  6. Written informed consent has been obtained.
  7. Written Authorization for Use and Release of Health and Research Study Information has been obtained.
  8. Agreement from the patient to allow photographs of the selected AK treatment area to be taken and used as part of the study data package.


  1. Females of child bearing potential (a female is considered of childbearing potential unless she is postmenopausal, i.e., no menses for at least 12 consecutive months, or is without a uterus).
  2. Location of the selected AK treatment area:

    1. anywhere on the face
    2. within 5 cm of an incompletely healed wound
    3. on the breast area of women
    4. on the dorsum of the hand
  3. AK lesions that have atypical clinical appearance e.g. hypertrophic, hyperkeratotic, recalcitrant disease (had cryosurgery on 2 previous occasions), cutaneous horns within the selected AK treatment area.
  4. Presence of suspected basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) within the selected AK treatment area or within 10 cm of the selected AK treatment area.
  5. Presence of known or suspected metastatic disease.
  6. History or evidence of skin conditions other than AK that would interfere with evaluation of the study drug (e.g. eczema, unstable psoriasis, xeroderma pigmentosa).
  7. Known sensitivity to any of the ingredients in the study drug.
  8. A cosmetic or therapeutic procedure (e.g. use of liquid nitrogen, surgical excision, curettage, dermabrasion, medium or greater depth chemical peel, laser resurfacing):

    • within 2 cm of the selected AK treatment area during the 4 weeks prior to screening visit
  9. Treatment with 5-fluorouracil, imiquimod, diclofenac, masoprocol or photodynamic therapy:

    • within 2 cm of the selected AK treatment area during the 24 months prior to screening visit or
    • anywhere during the 4 weeks prior to screening visit
  10. Treatment with other immunomodulators (e.g. vinblastine, podophyllin, colhamin, camptothecin), cytotoxic drugs (e.g. cyclophosphamide, azathiopine, chlorambucil, nitrogen mustard, methotrexate), or interferon/ interferon inducers:

    • within 4 weeks prior to screening visit
  11. Use of acid-containing therapeutic products (e.g. salicylic acids or fruit acids, such as alpha and beta hydroxy acids and glycolic acids), topical retinoids or light chemical peels:

    • within 2 cm of the selected AK treatment area during the 4 weeks prior to screening visit
  12. Treatment with psoralen plus UVA (PUVA) or use of UVB therapy:

    • anywhere during the 6 months prior to screening visit
  13. Use of systemic retinoids (e.g. isotretinoin, acitretin, bexarotene):

    • within 6 months prior to screening visit
  14. Anticipated excessive or prolonged exposure to ultraviolet light (e.g. sunlight, tanning beds).
  15. Use of topical salves, artificial tanners or topical steroids:

    • On the selected AK treatment area during the 4 weeks prior to screening visit
  16. Anticipated need for hospitalization (in-patient) or surgery (except that specified in exclusion criteria 8) during the study.
  17. Concurrent disease that suppresses the immune system (e.g. HIV, hepatitis).
  18. Uncontrolled systemic disease (e.g. uncontrolled hypertension [a systolic blood pressure of 180 mmHg or greater and/or a diastolic blood pressure of 110 mmHg or greater], poorly controlled diabetes [fasting blood sugar of 350 mg/dl or greater]).
  19. Use of systemic medications that suppress the immune system (e.g. cyclosporine, prednisone, methotrexate, alefacept, infliximab):

    • within 4 weeks prior to screening visit
  20. Current evidence of chronic alcohol or drug abuse.
  21. Current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study or entry into another investigational drug or device study while enrolled in this study.
  22. A condition or situation which in the Investigator's opinion may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study [e.g. patients who required hospitalization in the 2 months prior to screening for an acute or chronic condition].
  23. Selected AK treatment area within 5 cm of an AK lesion previously treated with PEP005, for those patients who have participated in earlier PEP005 topical gel trials. Patients enrolled in Treatment Phase 1 can not be re-enrolled into Treatment Phase 2.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00375739

  Hide Study Locations
United States, Alabama
Medical Affiliated Research Center, Inc.
Huntsville, Alabama, United States, 35801
United States, Arizona
Radiant Research
Tucson, Arizona, United States, 85710
United States, Arkansas
Burke Pharmaceutical Research
Hot Springs, Arkansas, United States, 71913
United States, Florida
Advanced Dermatology and Cosmetic Surgery
Clermont, Florida, United States, 34711
Dermatology Associates and Research
Coral Gales, Florida, United States, 33134
North Florida Dermatology Associates P.A.
Jacksonville, Florida, United States, 32204
Park Avenue Dermatology, PA
Orange Park, Florida, United States, 32073
Dermatology Associates of Tallahassee
Tallahassee, Florida, United States, 32308
Palm Beach Aesthetics
West Palm Beach, Florida, United States, 33401
United States, Georgia
Medaphase, Inc
Newnan, Georgia, United States, 30263
Gwinnett Clinical Research Centre, Inc
Snellville, Georgia, United States, 30078-3250
United States, Michigan
Henry Ford Health Center- Farmington Road
West Bloomfield, Michigan, United States, 48322
United States, New Mexico
Academic Dermatology Associates
Albuquerque, New Mexico, United States, 87106-5239
United States, New York
St. Luke's/Roosevelt Hospital Center Dermatology
New York, New York, United States, 10025
Mount Sinai Hospital School of Medicine
New York, New York, United States, 10029
United States, Ohio
University Dermatology Consultants, Inc., Dermatology Clinical Research Center
Cincinnati, Ohio, United States, 45219-4215
Radiant Research
Columbus, Ohio, United States, 43212
United States, Oregon
Oregon Medical Research
Centre9495 SW Locust St., Suite G Portland, Oregon, United States, 97223
United States, South Carolina
Radiant Research
Anderson, South Carolina, United States, 29621
Radiant Research
Greer, South Carolina, United States, 29651
United States, Texas
Dermatology Clinical Research Center of San Antonio
San Antonio, Texas, United States, 78229-3409
Dermatology Associates of Tyler
Tyler, Texas, United States, 75703
United States, Utah
Dermatology Research Centre
Salt Lake City, Utah, United States, 84124
United States, Washington
Skokane Dermatology Clinic, PLLP.
Spokane, Washington, United States, 99204
Sponsors and Collaborators
Principal Investigator: Lawrence Anderson, Dr
Study Chair: Peter Welburn, PhD Sponsor GmbH
  More Information Identifier: NCT00375739     History of Changes
Other Study ID Numbers: PEP005-006
Study First Received: September 11, 2006
Last Updated: January 26, 2016

Keywords provided by Peplin:
Actinic Keratosis
Solar Keratosis
Sun Spots

Additional relevant MeSH terms:
Keratosis, Actinic
Skin Diseases
Precancerous Conditions
Neoplasms processed this record on August 21, 2017